With this approval, telecommunication registration is completed for Actiste® Mini and the product is approved for telecom use in Qatar.

Brighter communicated earlier this year that the company signed a five-year distribution agreement with Al Danah Medical Company in Qatar regarding Brighter's pioneering product portfolio for diabetes management Actiste® ("Actiste Service").
 

"With Qatar's healthcare system being primarily state-run the outcome of the distribution agreement we communicated in February will largely depend on the Distributor's ability to win public tenders, but this approval is a significant milestone in the commercialization of the Actiste® portfolio," says Christer Trägårdh, acting CEO of Brighter AB.

Next step is to receive the same approval for Actiste® (with insulin injection) and to complete all remaining preparations including patient on-boarding and customer service setup.

For more information, please contact:

Investor Relations
ir@brighter.se

Certified Adviser

Brighter's Certified Adviser is Eminova Fondkommission AB, +46 [0)8 - 684 211 10, adviser@eminova.se, www.eminova.se.

About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to providing smarter care for chronic conditions. Our daily-care solutions are designed with a vision to facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers - aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG. https://brighter.se/